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SAMMANFATTNING
Cancer i bukspottkörteln är en förödande sjukdom med dålig prognos och
hög mortalitet. Majoriteten av cancertyperna är resistenta mot
cytostatikapreparatet gemcitabin, som ändå används för dess palliativa effekt.
För närvarande är sjukdomen obotlig och det är av högsta vikt att potenta
behandlingsalternativ utvecklas. Onkolytiska replikationsselektiva
adenovirus i kombination med cytostatika är en ny och lovande metod.
Tidigare studier har visat att två adenovirala mutanter, Ad5Δ19K och Ad5ΔΔ,
ökade celldöden av cancerceller i bukspottkörteln i kombination med
gemicitabin.
Syftet med denna studie var att, baserat på dessa fynd, ytterligare utreda
Ad5ΔΔ i kombination med chemoterapeutiska läkemedel samt bestämma
mekanismerna bakom ökad celldöd. Ad5ΔΔ är blockerad i den virala
E1ACR2-regionen. E1A är essentiell för S-fasinduktion och blockeringen gör
att viruset inte kan replikera i normala celler. Parallellt med studierna av
Ad5ΔΔ analyserades vildtypsformen av Ad5 för att bestämma skillnader i
celldödseffektivitet. Det visades att Ad5ΔΔ lyserade
bukspottkörtelcancerceller in vitro, ökade celldöden i kombination med
gemcitabin och irinotekan samt inducerade förändringar i cellcykeln hos
infekterade celler. Celler infekterade med Ad5ΔΔ uppvisade en ökad
polyploid cellpopulation vilket inte kunde observeras hos celler infekterade
med vildtyp. Dessutom påverkades uttrycket av virala gener av de
chemoterapeutiska läkemedlen samt ökade uttrycket av proteiner
involverade i mitos.
Ytterligare kunskap om mekanismerna bakom ökad celldöd till följd av
Ad5ΔΔ i kombination med cytostatika kan bidra till att vi besegrar
läkemedelsresistent bukspottkörelcancer i framtiden.4
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ABSTRACT
Pancreatic cancer is a devastating disease with poor prognosis and high
mortality. The majority of cancers show resistance to the chemotherapeutic
drug gemcitabine, which is used mainly for palliative effects. Currently, there
is no cure for pancreatic cancer and development of more potent treatments
are crucial. Use of oncolytic replication-selective adenoviruses is a novel and
promising approach. Previous studies have demonstrated that two adenoviral
mutants, Ad5∆19K and Ad5∆∆, enhanced cell-killing in pancreatic cancer
cells in combination with gemcitabine.
Based on these findings, this study was aimed at further investigations of
Ad5∆∆ in combination with chemotherapeutic drugs and to determine the
mechanisms  causing  potential  enhancement  of  cell-killing.  Ad5∆∆  has
deletions in the viral E1ACR2 region. E1A is essential for induction of S-phase
and the deletion makes the virus replication-defective in normal cells. The
wild type Ad5 (Ad5tg) virus was analysed in parallel in all experiments to
determine differences in cell-killing efficacy. It was demonstrated that Ad5∆∆
lysed pancreatic cancer cells in vitro, enhanced cell-killing in combination
with  gemcitabine  and  irinotecan  and  induced  aberrations  in  cell  cycle
progression of infected cells. Cells infected with Ad5∆∆ showed an increase in
polyploid cells, which was not observed with Ad5tg. In addition, the presence
of chemotherapeutic drugs affected viral gene expression and increased
expression of proteins involved in mitosis.
Further understanding of the mechanisms involved in the enhancement of
cell-killing observed for Ad5∆∆ and chemotherapeutic drugs might aid in
overcoming  drug  resistance  in  pancreatic  cancers  in  the  future.6
ABBREVIATIONS
Ad5tg  – Wild type adenovirus type 5
Ad5∆∆  – E1ACR2- and E1B19K deleted adenovirus type 5
Ad5∆19K – E1B19K deleted adenovirus type 5
CAR – Coxsackievirus and adenovirus receptor
CPE – Cytopathic effect
CR – Conserved Region
CT – Cycle threshold
Bcl2 – B-cell lymphoma 2
MHC I – Major Histocompatibility Complex Class I
DMEM – Dulbecco’s Modified Eagle Medium
EC50 – Half maximum effective concentration
E1 – Early Region 1
FACS – Flow cytometry assay
FCS – Foetal calf serum
GAPDH  – Glyceraldehyde 3-Phosphate Dehydrogenase
Gem  – Gemcitabine
HUVEC – Human umbilical-vein endothelial cells
Iri – Irinotecan
kRas – kRatSarcoma protein
MAD 2 – Mitotic arrest deficient protein 2
MOI  – Multiplicity of infection
MTS – 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphel)-2-
(4-sulfophenyl)-2H-tetrazolium
NHBC  – Normal human bronchial epithelial cells
nM  – Nano molar
uM  – Micro molar
mM  – Milli molar
PBS – Phosphate buffered saline
pRB  – Phosphorylated retinoblastoma
PFU  – Plaque forming unit
PMS  – Phenazine methosulfate
PI  – Propidium iodide
ppc  – Particles per cell
qPCR  – Quantitative polymerase chain reaction
TCID50 – Tissue culture infective dose at 50%
5-FU – 5-fluorouracil
PLEASE NOTE: In some graphs Ad5∆∆ is named Ad5DD.7
INTRODUCTION
Pancreatic Cancer
Pancreatic cancer is the 11
th most common form of cancer in the UK (Cancer
Research UK http://info.cancerresearchuk.org ) and the 4
th most common
cause of cancer death worldwide (Mariharan, D. et al. 2008). Among the 21
most common forms of cancer in England, pancreatic cancer shows the lowest
relative  survival rate,  of less than  3%, after  5 years  (Office  for National
Statistics  2010).  In  comparison  to  other  forms  of  cancer,  survival  and
development  of  efficient  therapies  targeting  pancreatic  cancer  have  not
significantly improved over the last 30 years (Cancer Research UK). Since the
symptoms are vague and diffuse, clinical presentation and diagnosis often
occur first when the cancer is at an advanced stage. It is common that
metastases are already present when the patient is diagnosed. Currently, the
only curative treatment to date is radical surgery, but due to the often late
diagnosis, inconvenient anatomical location and development of metastases,
it is almost impossible to resect all tumors. In addition, pancreatic cancers are
highly resistant to the currently available chemotherapeutic drugs such as
gemcitabine and 5-fluorouracil (5-FU). Therefore, it is imperative to develop
new therapies.
The majority of pancreatic cancers are ductal adenocarcinomas. Of these, 50-
75% are mutated in the p53 gene, allowing cells to bypass DNA damage
checkpoints  and  the  induction  of  apoptosis.  Approximately  90%  of  all
pancreatic cancers have an activating mutation of the oncogene K-ras and an
inactivating  mutation  of  the  tumour-suppressor  gene  CDKN2A.  The
activation of K-ras results in an aberrant activation of signalling pathways
promoting cell proliferation and survival. Inactivation of CDKN2A leads to
loss  of  the  tumour  suppressor  gene  p16,  an  important  regulator  of  the
progression from G1 to S-phase in the cell cycle (Hidalgo, M. 2010). Together,8
these and other common cancer-related mutations lead to failure in growth
arrest, proliferation and promotion of metastasis (Morton, P J. et al. 2010).
Chemotherapeutic drugs act palliatively, but do not cure pancreatic cancer. 5-
FU) was the only drug used in pancreatic cancer for many decades. In 1997,
another chemotherapeutic drug with significantly better clinical responses
emerged:  gemcitabine   (Li,  J  &  Wasif,  S  M.  2009).  Gemcitabine  (2’,  2’-
difluorodeoxycitidine)  is  a  pyrimidine  nucleoside  analogue,  which
incorporates  in  DNA  and  RNA  stopping  replication  and  translation
respectively, ultimately leading to apoptosis. It mainly targets cells in S-phase
but also inhibits cell progression from G1 to S-phase. Since 1997, gemcitabine
has been the drug of choice for advanced pancreatic cancer. However, despite
the  benefits  in  comparison  to  5-FU,  the  overall  objective  responses  are
modest. Only 25% of patients actually benefit from gemcitabine therapy, since
many types of pancreatic cancer show resistance to the drug. The mechanisms
for sensitivity and resistance to gemcitabine have been widely investigated in
order to identify molecular markers for treatment responses (Akada, M. et al.
2005). Mutant p53 (Galmarini, CM. et al. 2002) (presents in the majority of
pancreatic cancers) and Bcl-XL ((Shi, X. et al. 2002) & (Schniewind, et al. 2004)),
both  involved  in  apoptosis,  have  been  identified  as  possible  molecular
markers of chemoresistance to gemcitabine. It has also been demonstrated
that  Bcl2/adenovirus  E1B  19kDa  protein  interacting  protein  (BNIP3)  is
expressed at lower levels in pancreatic cell lines resistant to gemcitabine.
BNIP3 is a proapoptotic protein in the Bcl-2 family (Akada, M. et al. 2005).
Various gemcitabine based combination chemotherapies have been designed
trying to improve efficacy, but none has been demonstrated to be superior to
gemcitabine mono therapy. One of the chemotherapeutic drugs tested in
combination with gemcitabine is irinotecan (camptothecin), normally used for
the treatment of colorectal cancer (Li, J & Wasif, S M. 2009). Irinotecan inhibits
DNA Topoisomerase I, an enzyme essential for religation of single strand
breaks during DNA-replication, the cytotoxic effect targets mainly cells in S-
phase with active DNA synthesis, but also cells in G2-phase (Pommier, Y.
2006).9
Oncolytic adenovirus as therapeutics
Viral gene therapy is a promising developing field in the battle against cancer.
Adenoviruses have been developed as efficient tools for cancer treatments
during the last decade, because of efficient transgene delivery, transduction of
both dividing and non-dividing cells, ease of production to high titres and
extensive understanding of the viral life cycle ((Wu, Q. et al. 2001) & (Douglas,
JT. 2007)). Through  manipulating  the  viral genome,  for example  via the
deletions or insertions of genes, the virus can be tailored to match specific
gene mutations in the cancer cell ((Young, S L. et al 2006) & (Anurag, S. et al.
2009)). In addition, the virus does not integrate in the host genome and has
been proven safe in humans with promising efficacy in many clinical trials
(Douglas, JT. 2007). Adenoviruses can accommodate up to 2kB (5%) of foreign
DNA without significant effects on stability and infectivity (Wu, Q. et al.
2001). Adenovirus serotypes 5 and 2, have been most frequently used in
cancer gene therapy to date (Anurag, S. et al. 2009).
Human adenovirus is specific to humans and does not replicate in murine
cells. Adenoviral in vivo models on cancer must therefore be performed using
immunodeficient mice with human tumour xenografts. Other limitations for
the therapeutic uses of Ad5 are the difficulties with systemic delivery in
humans. Human erythrocytes bind and inactivate Ad5 to protect against
systemic infection. In contrast to mouse erythrocytes, it was demonstrated
that human erythrocytes express coxsackievirus and adenovirus receptor
(CAR). This is the same receptor as the virus uses for cell entry during
infection,  resulting  in  Ad5  sequesteration  by  erythrocytes  and  final
elimination  by  the  liver  (Carlisle,  C.  R.  et al.  2009)  Until  this  complex
formation has been overcome, for example by detargeting of viruses, anti-
cancer therapy using Ad5 must be delivered non-systemically, for example
via intratumoral or intracavitary injections. This limits the possibilities to
reach all tumours.10
Adenovirus
The  name  adeno is derived from where this virus was first isolated, the
adenoid  tissue,  in 1956 (Shenk,  T E.  2001). Infection  with adenovirus  in
immuno-competent individuals is mild. Dependant on the serotype the virus
can  cause  upper  respiratory  tract  infections,  gastroenteritis  or
keratoconjunctivitis, and symptoms similar to a mild flu (Wu, Q. et al. 2001).
The human adenovirus has been divided into 51 serotypes, based on their
resistance to neutralisation by antisera. The serotypes are then classified into
subgroups based on their ability to agglutinate erythrocytes. Adenovirus type
2 and 5 are the most studied serotypes, and therefore are the most important
in adenoviral gene therapy (Shenk, T E. 2001). The Ad5 genome is a linear,
double-stranded DNA of approximately 36kb. The genome is surrounded by
an  icosahedral  capsid.  The  capsid  can  be  described  as  a  protein  shell
composed of predominantly three proteins: hexon, penton base and fiber
(Wu, Q. et al. 2001).
Adenovirus can infect all epithelial cells. When entering the cell, the fiber
knob attaches to CAR leading to receptor-mediated endocytosis. MHC I can
probably also serve as a receptor for Ad5 (Shenk, T E. 2001). The viral genome
is released from the viral capsid in the endosome and transported to the
nucleus via microtubules (Fig. 1). Once the genome is in the nucleus the early
genes (E1-4) are expressed (Hakkarainen, T & Hemminki, A. 2001). Viral
replication leads to cell lysis and release of new adenoviruses.11
Fig.  1  The  adenoviral  life  cycle.  The  fiber  knob  attaches  to  CAR  leading  to
receptor-mediated endocytosis. The viral genome is released from the viral capsid
in the endosome  and  transported  to the nucleus via  microtubules.  Viral  gene
expression starts once the genome has reached the nucleus. Replication leads to
lysis  of  the  cell  and  release  of  new  viruses  (Hakkarainen,  T  &  Hemminki,  A.
2001).
Viruses manipulate their host cells by expressing viral proteins that can either
induce or inhibit cellular functions to enable the viral life cycle to proceed.
Through this viral mimicry, the virus can prevent apoptosis and evade the
host’s immune-response (Young, S. L. et al. 2006). The adenoviral genome
(Fig. 2) has been described in terms of early (E) and late (L) genes/proteins
depending on when they are expressed in the infection cycle. This does not
always hold true, since some genes are expressed at low level throughout the
entire replicative cycle, but it can be used to simplify the understanding of the
genome (Shenk, T E. 2001).12
Fig. 2 Schematic diagram of the adenoviral genome (Ad5). The length of genome
is divided into 100 measurement units (m.u), two inverted terminal repeats (ITR)
a major late promotor (MLP) and the early (E1-E4) and late (L1-L5) structural
genes. Arrows indicate the direction of transcription (Wu, Q. et al 2001).
The adenoviral genome carries four early transcription units: E1 (A and B),
E2, E3 and E4.
The E1A gene is the first gene to be expressed when the viral genome has
reached the nucleus. It induces expression of other early genes and forces the
cell to enter S phase. Retinoblastoma protein (Rb) is a negative controller of
cell cycle progression. It has a pocket domain through which it binds and
inactivates E2F, a transcription factor inducing S phase. When Rb binds to
E2F, the progression from G1 to S phase is inhibited (Fig 3).  The adenoviral
E1A proteins, 12- and 13S, both contain two independent domains, which can
bind Rb: E1ACR1 and -2. The interaction is not yet fully understood, but it
seems as if E1ACR1 binds to the same site as E2F whilst E1ACR2 binds to
another site on Rb. It has been shown that E1ACR2 is the essential domain for
the formation of the Rb complex (Fattaey, R A. et al. 1993). When E1ACR2
binds Rb, E2F is released and the cell pushed into S-phase.13
Fig. 3 Normal cell cycle. Checkpoint R regulates progression from G1-S. pRB is a
negative controller of this checkpoint.
(http://kirschner.med.harvard.edu/files/html/research.shtml)
The E1B gene encodes two proteins, E1B-55K and E1B-19K, which block
apoptosis that is induced by E1A. The E2 proteins function directly in viral
DNA replication. The E3 region encodes several proteins that modulate the
host immune-response to protect the infected cell from cytokine-induced cell-
killing and the E4 proteins mediate transcriptional regulation, modulate DNA
replication and prevent activation of the DNA-damage response. (Shenk, T E.
2001).
Oncolytic replication-selective adenoviral mutants
The rationale for the use of replication-selective oncolytic viruses is that the
mutants can lyse cancer cells but spares normal cells. There are different ways
to achieve this. One way is to construct a virus that is replication-attenuated
in the intracellular environment of a normal cell but has its full efficacy in the
cancer cell, an oncolytic replication-selective virus. The viral mutant can thus
replicate and lyse cancer cells and spread within the tumour with limited
amplification and cytotoxicity in normal tissue (Fig. 4). Infected normal cells
subsequently  undergo  apoptosis  and  viral  spread  in  non-cancer  cells  is
limited. Cycling normal cells provide a similar environment as cancer cells,14
and the virus could potentially replicate in these cells but not in quiescent
cells (Young, S. L. et al. 2006).
Fig. 4 The theoretical principle of an oncolytic replication-selective adenovirus in
action.
For the host, the apoptotic pathway is an important defence-mechanism in
virus-infected cells. Apoptosis is induced in response to the presence of viral
DNA and E1A. To inhibit induction of apoptosis viral proteins are expressed
(E1B,  E4).  In  cancer  cells,  these  apoptotic  pathways  are  commonly
deregulated. The adenoviral gene E1B encodes two proteins, E1B19K and
E1B55K,  which  block  apoptosis.  The  first  oncolytic  replication-selective
adenoviral mutant to be evaluated clinically, ONYX-015 (dl1520), was deleted
in  the  E1B55K  gene  (Aghi,  M  &  Martuza,  RL.  2005).  ONYX-015  was
engineered to selectively replicate in and lyse p53-deficient cancer cells, not
being able to inhibit the functional p53 in normal cells (Khuri, R F. et al. 2000).
The E1B55K protein binds p53 and antagonizes the ability of p53 to block cell
cycle progression and induce apoptosis by inhibiting its activation function.
E1B55K also collaborates with E1A to activate quiescent cells to progress in
cell cycle (Shenk, T E. 2001). However, it was later discovered that E1B55K
was  essential  for  viral  mRNA  export  making  ONYX-015  too  attenuated
resulting in poor efficasy (O’Shea, C C. 2005).
The second E1B protein, E1B19K, is a viral Bcl-2 homolog that inactivates the
pro-apoptotic Bcl-2 family members, BAX and BAK, so that apoptosis is
inhibited (Berk, J A. 2005). By deleting this gene, the virus cannot prevent15
apoptosis in normal cells. Mutants lacking E1B19K (∆E1B19K)  have been
shown to improve efficacy of DNA-damaging drugs such as gemcitabine
through increasing apoptosis-like cell death (Leitner, S. et al. 2009)
Recently, an oncolytic mutant was engineered (Fig. 5), a double deleted Ad5
virus, Ad5∆∆, with deletions in the ∆E1ACR2 region for tumour selectivity
and deletions in the ∆E1B19K gene for attenuated replication in normal cells
(Oberg, D. et al.  2010). Ad5∆∆  has been  shown to  have high  cell-killing
activity  in  pancreatic  carcinomas  (Oberg,  D.  et al.  2010)  and  has  been
demonstrated  to  enhance  cell-killing  in  combination  with  the
chemotherapeutic drugs gemcitabine and irinotecan in vitro (Dr. Cherubini &
Kallin, unpublished work). This synergistic effect was previous demonstrated
in the single deleted Ad5∆19K (Leitner, S et al. 2009).
Fig.  5  Schematic  drawing  of localisation  of deletions  in  Ad5∆19K  and Ad5∆∆
compared to Ad5tg (adapted from: Wu, Q. et al 2001 & Oberg, D. et al 2010).
Tumour selectively by E1ACR2-deletion. As described above, the E1ACR2-
domain competes with E2F for access to the Rb pocket domain, blocks the
binding site for E2F and forms a complex with Rb. Free E2F activates the
transcription of a series of genes important for S phase and cell growth (Fig.
6). When E1ACR2 is deleted, it cannot bind to Rb and is unable to stimulate
cellular  DNA  synthesis  (Shenk,  T  E.  2001).  In  most  cancers,  Rb  is
phosphorylated  (pRb)  and  thereby  inactivated,  free  E2F  can  activate
transcription and cell cycle progression.16
Fig.  6  The  adenoviral  E1ACR2  competes  with  E2F  for  access  to  the
Retinoblastoma  protein  pocket  domain.  Free  E2F  activates  transcription  and
i n d u c e s   S-phase.  (adapted  from:
http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/T/TumorSuppressorGene
s.html)
To date, most oncolytic viruses evaluated in the clinic have E3-deletions, to
shorten the viral survival. E3 is an immunoregulatory gene, which prolongs
the virus T1/2 in vivo. Thus, it has been shown that oncolytic mutants with
intact E3-region replicate more efficiently and show enhanced anti-tumour
effect ((Wang, Y. et al. 2003) & (Oberg, D. et al. 2010)). Both Ad5∆19K and
Ad5∆∆ have an intact E3 gene.17
Project aims
The  adenoviral  mutant  Ad5∆∆  (E1ACR2-  and  E1B19K-  deleted)  in
combination with the chemotherapeutic drugs gemcitabine and irinotecan has
been shown to enhance cell-killing in pancreatic cancer cells. This project was
aimed at establishing whether this effect also was observed in additional
pancreatic cancer cell lines and if so, investigating mechanisms causing the
more than additive increase in cell-death.
•  Does Ad5∆∆ lyse pancreatic cancer cells efficiently?
•  Does  Ad5∆∆  sensitize  cancer  cells  to  the  chemotherapeutic  drugs
gemcitabine and irinotecan?
•  How  does  Ad5∆∆  in  combination  with  drugs  affect  cell  cycle
progression and cellular protein expression?
•  Is  Ad5∆∆  replication-attenuated  in  normal  human  umbilical-vein
endothelial cells?
•  How do the combination treatments kill the cancer-cells?
Finding a new treatment for pancreatic cancer is crucial. The results of the
experiments in this project will, hopefully, bring the Ad5∆∆ virus a step closer
to  clinical  trials  as  a  new  treatment  for  pancreatic  cancer.  Further
understanding  of  the  mechanisms  behind  the  greatly  improved  efficacy
observed for Ad5∆∆ in combination with chemotherapeutic drugs might aid
in the understanding of drug resistance.18
MATERIALS AND METHODS
Cell lines and normal cells. Human pancreatic adenocarcinoma cell lines used
for this project were MIA-PaCa-2 and AsPC-1 (Table 1) provided from Cell
Services,  Clare  Hall,  Cancer  Research  UK.  MIA-PaCa-2  and  AsPC-1  are
classified as intermediate sensitive to gemcitabine (Akada, M. et al. 2005).
Cell line Differentiation Source p53 K-ras CDKN2A SMAD4
MIA-PaCa-2
Poor Primary
tumor
Mutation
(-)
Point
mutation
Mutation
(+)
Point
mutation
Mutation
(-)
Homozygous
deletion
None
Wild type
AsPC-1
Moderate Ascites Mutation
(-)
Frameshift
Mutation
(+)
Point
mutation
Mutation
(-)
Frameshift
Mutation
(-)
Point
mutation
Table 1 Genetic aberrations in MIA-PaCa-2 and AsPC-1. Activating (+) or
inactivating (-) mutations (Moore et al. 2000 and Sipos et al. 2002).
JH293 cells, a subclone of the human embryonic kidney cell line HEK293
(Wang, Y. et al. 2005) was used for half maximum tissue culture infective dose
(TCID50),  (Cell Services, Cancer Research UK) were cultured according to the
manufacturer’s instructions.
Normal human umbilical vein endothelial cells, HUVEC, were cultured in
endothelial cell basal medium-2 (EBM-2) according to the manufacturer’s
instructions (Lonza Clonetic®).
Cell culture. The cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) high glucose (4.5 g/L) (PAA Laboratories GmbH, Pasching, Austria)
supplemented with 10% foetal calf serum (FCS) (PAA Laboratories GmbH,19
Pasching, Austria) and 100 units/mL penicillin, 100mg/L streptomycin (PAA
Laboratories GmbH, Pasching, Austria). The cells were incubated in 37˚C
with CO2 levels kept constant at 5% for MIA-PaCa-2, and 10% for AsPC-1.
The cells were propagated twice a week and transferred into new flasks
before reaching confluency. The media was aspired and the cells washed with
phosphate  buffered  saline  (PBS),  before  adding  the  enzyme  trypsin  to
deattach  the  monolayer.  Once  the  cells  were  deattached  the  enzymatic
reaction was stopped through addition of 10% FCS DMEM. Cells needed for
experiments were plated at the time of propagation.
Adenoviruses. The following mutants of adenovirus type 5 were used: Ad5tg
(Ad5 wild-type), Ad5∆∆ (Ad5tg with E1ACR2- and E1B19K-deletions) and
Ad5∆19K  (Ad5tg with E1B19K-deletion). The Ad5tg genome was derived
from the pTG3602 plasmid (Dr. M. Methali, Transgene) and all mutants were
generated by homologous recombination with shuttle plasmids containing
the respective E1ACR2 and E1B19K deletions as described (Oberg, D. et al.
2010). All the mutants are replication-competent.
Chemotherapeutic drugs. Gemcitabine (2’,2’-difluorodeoxycitidine, Gemzar®,
Eli-Lilly, Indianapolis, IN) and irinotecan (camptothecin, Irinotecan HCL,
Hospira UK Limited) were used in this project. The stock concentration for
gemcitabine and irinotecan was 100mM and 34mM respectively. Gemcitabine
was stored at -20˚ and irinotecan at room temperature.
Cell-killing  assays. The  MTS  assay  (3-(4,5-Dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphel)-2-(4-sulfophenyl)-2H-tetrazolium)  is  a  colorimetric
assay that measures the changes in colour caused by mitochondrial enzymes
active only in live cells. In the presence of PMS (phenazine methosulfate),
mitochondrial enzymes convert MTS to formazan with an absorbance at
490nm. The absorbance value is directly proportional to the number of live
cells enabling quantification of cell death.20
The  MTS  assay  was  used  to  determine  cell-killing  72  hours  after  viral
infection and/or treatment with chemotherapeutic drugs. Dose response
curves were generated to both virus and drugs to determine 50% and 20% cell
death  for  EC50-  and  EC20-  values  respectively.  The  chemotherapeutic
drug/viral concentration that resulted in 20% or less cell death alone, was
used as the constant concentration in the combination treatment. Each data
point was generated from triplicate samples and the experiment repeated up
to 4 times for each condition.
Infection for cell-killing assay
Cell lines analysed: MIA-PaCa-2 and AsPC-1
10000 cells per well were seeded on sterile 96-wells plates in 10% FCS DMEM
(100µl), 24 hours before infection/treatment. The outer rows were filled with
100µl media alone, to help maintain humidity. Each condition was tested in
triplicates:  three  wells  with  the  same  conditions.  On  the  day  of
infection/treatment, virus and chemotherapeutic drugs were prepared in
DMEM supplemented with 2% FCS. The MTS assay was first set up for virus
and  chemotherapeutic  drug  respectively  and  then  for  combination
treatments. The concentrations used in the combination treatments were
based on virus and chemotherapeutic drug dose-response curves and were
selected at a dose that resulted in <20% cell death on its own.
The serial dilution for virus started at 1x10
5 particles per cell (ppc) with ten 5-
fold dilutions. The chemotherapeutic drugs were diluted 3-fold 10 times,
starting at concentrations 100µM, 40µM, 10µM and 1µM for gemcitabine, and
3.4mM and 1mM for irinotecan.
Combination treatment with constant concentration of chemotherapeutic drug and
serial dilution of virus. The concentrations of chemotherapeutic drug were
prepared  in  2%  FCS  DMEM.  Two  different  concentrations  of  each
chemotherapeutic drug were used in each combination experiment, causing
<20% cell death alone. 90µl of the chemotherapeutic drug solution was added
to each well. 10µl from each viral dilution was added to the wells, all in21
triplicates.  Three  rows  were  left  without  any  virus:  one  with  just  the
chemotherapeutic drug solution as control for drug-induced cell death, one
with just cells as control for maximum cell viability in cells alone and one
with just media background control (Fig. 7 A and B).
A
B
Fig. 7 A. Organisation of combination treatment with constant chemodrug and
serial dilution of virus on the 96-well plate. B. Example of 40nM gemcitabine and
serial dilutions of Ad5tg and Ad5∆∆ respectively, in triplicates.22
Combination treatment with constant concentration of virus and serial dilution of
chemotherapeutic drug. The virus dilutions were prepared in 2% FCS DMEM.
Two different concentrations of each virus were used, based on EC20-values in
previous MTS-assays. The concentration of virus on its own resulted in <20%
cell  death.  The  experiment  was  performed  as  described  above  with  the
exception that one row contained just virus instead of just chemotherapeutic
drug (Fig. 8 A and B).
A
B
Fig.  8 A. Organisation of combination treatment with constant virus and serial
dilution of chemodrug on the 96-well plate. B. Example of Ad5tg 50ppc and serial
dilutions of gemcitabine and irinotecan respectively, in triplicates.23
72 hours post infection, media was discarded and 100µl MTS solution/well
was added (80% DMEM media 0% FCS, 20% MTS, 1% PMS). The plates were
read in an ELISA microplate reader at a wavelength of 490nm (Opsys MR,
Dynex Technologies). The values were transferred to the EXCEL graphing
program for calculations.
CALCULATION OF CELL DEATH IN PERCENTAGE:
100 – (((sample – average background) / average control) * 100)
CALCULATION OF CELL DEATH IN PERCENTAGE FOR COMBINATION
TREATMENTS:
Combination treatment with constant concentration of drug
100 – (((sample – average background) / (average drug alone – average
background) * 100)
Combination treatment with constant virus
100 – (((sample – average background) / (average virus alone – average
background) * 100)
Infection for Western Blotting and Flow Cytometry Assay
Cell line analysed: MIA-PaCa-2
 24 hours before infection, 1x10
6 cells/plate were plated in 10cm ∅ plates with
10ml of 10% FCS DMEM/plate. 3 plates per condition were plated, one for
each time point: 24, 48 and 72 hours, plus one plate needed for cell counting
before infection (Table 2).
Mock
Ad5tg 100 PPC
Ad5∆∆ 100 PPC
Gem 40nM
Ad5tg 100 PPC + Gem 40nM
Ad5∆∆ 100 PPC + Gem 40nM
Iri 15µM
Ad5tg 100 PPC + Iri 15µM
Ad5∆∆ 100PPC + Iri 15µM
Table 2 Conditions analysed for western blotting and FACS.24
The doses of viruses and chemotherapeutic drugs were chosen according to
results  from  MTS  assays  described  above.  These  suboptimal  doses  of
gemcitabine and irinotecan resulted in <20% cell death on its own, but in
increased cell death when combined with Ad5∆∆.
On the day of infection one
plate was trypsinised to count the cells. Viral dilutions of 100 ppc were
prepared in 0% FCS DMEM, 2ml for each plate. The media was aspired and
2ml of the respective viral dilution was added to the plates, whereas 2ml of
0% FCS DMEM was added to the control plates (e.g mock infected cells). The
cells were harvested 24, 48 and 72 hours after this time point (=infection). All
plates  were  incubated  at  37˚C  for  2  hours,  the  optimal  time  for  virus
transduction of cells in culture. After 2 hours the media from all plates was
aspired and 6ml of the chemotherapeutic drug dilutions in 10% FCS DMEM
was added to the plates, whereas 6ml of 10% FCS DMEM was added to the
drug free plates. All plates were then incubated at 37˚C until harvesting.
The media was removed and the cells were trypsinised at 24, 48 and 72 hours
after  infection,.  Media  and  cells  were  combined  and  centrifuged,  the
supernatant removed and the pellet was resuspended in 2ml of PBS. 1ml was
transferred to Eppendorf tubes for preparation of protein lysate for Western
blotting and 1ml was transferred to FACS tubes. Both tubes were centrifuged
again and the supernatants removed.
For Western blotting:  The pellets were resuspended in RIPA buffer (50mM Tris
HCl pH 8.0, 150mM NaCl, 1 mM PMSF, 1 mM EDTA, 1% (w/v) Igepal CA-
630 (NP-40), 0.1% (w/v) SDS, 1 tablet of protease inhibitor (Roche) per 10 ml
RIPA buffer, kept at 4˚C for 30 minutes and stored at -20˚C.
For Flow Cytometry Assay: The pellets were resuspended in 1ml 70% EtOH
4˚C, vortexed and stored at 4˚C (if analysed within 2 weeks, otherwise stored
in –20°C).
Western Blotting. Cells were infected with viruses/chemotherapeutic drugs,
harvested after 24, 48 and 72 h as described above. The proteins in each25
sample were quantified by the Bradford assay (Bio Rad) and then diluted in
RIPA buffer to a final concentration of 2µg protein/µl per sample. After
diluting the samples, the proteins were quantified again to calculate the final
protein concentration. A 10% SDS/PAGE acrylamide gels were prepared. The
percentage of the gel was chosen according to the molecular weights of the
proteins of interest. Each gel was loaded with 14 samples plus ladder (250-
11kD). 20µg of protein was loaded per well. The proteins were separated on
the  gel  and  transferred  to  a  polyvinyl-idene  fluoride  (PVDF)  transfer
membrane (GE Healthcare). For E1A and adenoviral capsid proteins, the
membrane was cut at 55kD and incubated with primary antibodies (ab)
separately since the antibodies needed different secondary antibodies (anti-
mouse  respective  anti-rabbit).  The  membranes  were  incubated  with  the
primary antibodies at 4˚C over night (Table 3).
Dilution Animal Storage Mol. weight Supplier Anti-ab
Dilution
E1A 1:1000 Mouse +4˚C 35-46kD Santa Cruz 1:2000
Ad-Capsid 1:10000 Rabbit +4˚C 55-130kD Abcam 1:2000
Aurora-A
Kinase
1:500 Mouse -20˚C 46kD BD Biosciences 1:2000
Aurora-B
Kinase
1:500 Mouse -20˚C 41kD BD Biosciences 1:2000
MAD 2 1:2000 Mouse -20˚C 24kD BD Biosciences 1:2000
Vinculine 1:10000 Mouse +4˚C 130kD Abcam 1:2000
Table 3 The primary antibodies to the proteins E1A, adenoviral capsid proteins,
Aurora A- and B-kinase and MAD-2
After washing, they were incubated with the secondary antibody for 2 hours
in room temperature or 4 hours at 4˚C. Anti-mouse was used as secondary
antibody for E1A, Aurora-A Kinase, Aurora-B Kinase and MAD-2, and anti-
rabbit for adenoviral capsid proteins. After washing, the membranes were
covered with a solution of detection reagent and the film developed in the
dark room. The membranes were washed again and re-incubated over night26
with antibodies against Vinculine. Vinculine was used as loading control for
all membranes. For further details see Western Blot Protocol, Appendix 1.
Flow  Cytometry  Analysis.  Cells  were  infected  with
viruses/chemotherapeutic drugs, harvested after 24, 48 and 72 h as described
above. After fixation in 70% EtOH for at least 24h the cells were centrifuged
and washed with PBS, supernatant was discarded and the cell pellets were
treated with 100 µg/ml RNAse and 50µg/ml Popidium Iodide (PI). PI is
commonly used to quantitatively assess DNA content. All samples were
analysed  by  flow  cytometry  FACScalibur  (Becton  Dickinson,
Immunocytometry Systems, Belgium) with CellQuest Pro Software version
4.0.2, acquiring 10000 cells/sample. During the process, adjustments were
made so that the G1 peak was positioned at 200 FL3-H/Pulse Width to allow
more accurate comparison between samples. It was essential to exclude cell
doublets, but to include polyploid cells, this was performed by gating which
cells to take into account (Fig. 9).
Fig. 9 Description of how the gates were adjusted for mock at each time point,
24, 48 and 72h.
Once the single cell population was identified the percentage of cells in G1, S-
phase and G2/M could be estimated by subjectively applied markers for G1,27
S-phase and G2/M. The markers were set based on the profile of untreated
cells (mock) at each time point (24, 48 and 72 hours), and applied for samples
at the relevant time point (Cancer Research UK).
Infection  for  quantitative  polymerase  chain  reaction  (qPCR)  and  half
maximum tissue culture infective dose (TCID50)
Cells analysed: HUVEC
500000 cells/well were seeded in 6-wells plates in 3ml of endothelial cell basal
medium-2 (EBM-2 Lonza, Clonetic®). The media was changed every 48 hours
until the cells were confluent/growth arrested, 10 days after plating. Each
sample was prepared in duplicates and 1 extra well/virus was plated to
collect viruses 4 hours post infection, as control for viral uptake. One well was
also needed for cell counting on the day of infection (Table 4). When the cells
had reached confluence/growth arrest the infection was according to the
procedure described for Western blotting and FACS. See above. The only
difference was that cells were also harvested 4 hours post infection.
Mock
Ad5tg 100 PPC
Ad5∆∆ 100 PPC
Ad5∆19K 100 PPC
Table 4 Conditions analysed for qPCR and TCID50.
Cells were harvested at 4, 24, 48 and 72 h post infection. 1ml of the media was
collected, attached cells were trypsinised and media and cells were combined.
After mixing, 500µl was transferred to cryovial tubes and stored at –80°C (for
TCID50). The remaining 500µl was centrifuged and washed with PBS. The
pellet was resuspended in 200µl PBS and stored at –20°C (for qPCR).
Quantitative polymerase chain reaction. DNA  was  extracted  from  the
samples using the QIAGEN kit (QIAGEN®) according to QIAamp® DNA28
Mini and Blood Mini Handbook Spin protocol for Blood and Body Fluids.
DNA concentrations were determined by Nanodrop (ThermoScientific) and
adjusted to 4ng/µL with autoclaved ddH20. 5µL/well was added to a 96-well
plate. Forward (100nM) and reverse (100nM) primers for E2A and GAPDH
were prepared with the Power SYBR Green Master Mix (Applied Biosystems)
and added to each well. The reactions were run on qPCR (7500 Real Time
PCR System; Applied Biosystems) and analyzed by the System SDS software.
Each  sample  was  made  in  duplicates,  ie  2  reactions  for  GAPDH
(glyceraldehydes 3-phosphate dehydrogenase) (normalisation reaction which
should always produce a PCR product) and 2 reactions for E2A (a viral
specific PCR product to evaluate viral DNA content as part of total DNA).
Sterile water was used as a negative control for both GAPDH and E2A. The
cycle threshold (CT) value for GAPHD was subtracted from the CT value for
E2A and all duplicate values averaged. Calculations for average fold change
relative to Ad5tg 24h was made in EXCEL using the 2
-∆∆
CT method: dCT= (CT
E2A-CT GAPDH), ddCT= (dCT-dCT for Ad5tg 24h), fold change= POWER (2,
-ddCT) (Tichopad, A. et al. 2003).
The experiment was repeated 3 times, using samples that derived from the
same infection/collection. The first 2 repeats contained samples from the
same aliquots, whereas the third repeat contained newly prepared dilution.
Adenovirus replication assay. TCID50 was used for analysing viral replication
in HUVEC. The viruses analysed were: Ad5tg, Ad5∆∆, Ad5∆19K at 24, 48 and
72 hours post infection. Each sample was prepared in duplicates. An internal
Ad5 (batch 290409) with known activity was included as control and analysed
in triplicates. For the samples at 24 hours the dilutions used were 1x10
-5 - 10
-11
and for 48 and 72h, including the control, 1x10
-7 - 10
-13. The last row on the
plate had no virus (negative control). After 10 days the plates were inspected,
well  by  well,  to  determine  the  cytopathic  effect  (CPE)  of  each  sample.
Infectious  units  per  cell  were  calculated  for  each  sample  according  to
Spearman-Karber’s formula ((Karber, G. 1931) & (Wang, Y et al. 2003)) and
expressed as plaque forming units (pfu)/cell. For more details see TCID50
protocol, Appendix 2.29
Statistics. Statistical significance between EC50-values was calculated using
unpaired t-test with 95% confidence intervals in GraphPad Prism® software.
Pictures were made in Adobe Illustrator and Adobe Photoshop.30
RESULTS
Cell-killing assays
To determine if the pancreatic cancer cell lines MIA-PaCa-2 and AsPC-1 were
sensitive to the adenoviral mutants Ad5tg and Ad5∆∆, cell-killing assays were
performed with serial dilutions of virus.
MIA-PaCa-2 and AsPC-1 are sensitive to both wildtype adenovirus type 5
(Ad5tg)  and  to  the  replication-selective  E1ACR2-  and  E1B19K-deleted
adenoviral mutant (Ad∆∆). Dose-dependent cell death was observed in MIA-
PaCa-2 cells (Fig. 10 A) and AsPC-1 cells (Fig. 11 A) 72 hours after infection
with Ad5tg and Ad5∆∆. The highest dose of both viruses, 1x10
5 ppc, resulted
in 95-100% cell death in MIA-PaCa-2. AsPC-1 was more resistant; more than
70% cell killing could not be achieved with 1x10
5 ppc for either virus. There
were  no  differences  between  Ad5tg  and  Ad5∆∆  at  the  maximum
concentration of virus (1x10
5 ppc).   However, the cytotoxic effect of Ad5tg
was significantly higher than Ad5∆∆, at the effective concentration killing
50% of cells (EC50) in both cell lines (Fig. 10 B and 11 B).31
MIA-PaCa-2
A
B
Fig.  10  MIA-PaCa-2  cells  are  sensitive  to  both  Ad5tg  and  Ad5∆∆.  A.  Dose-
response curves in MIA-PaCa-2 cells 72 h after infection with Ad5tg and Ad5∆∆.
One representative experiment out of 10. B. Comparison of EC50-values for Ad5tg
and Ad5∆∆, averages ± SD, n=10, **p<0.0132
AsPC-1
A
B
Fig. 11 AsPC-1 cells are sensitive to both Ad5tg and Ad5∆∆. A. Dose-response
curve in AsPC-1 72 h after infection with Ad5tg and Ad5∆∆. One representative
experiment  out  of  6.  B.  Comparison  of  EC50-values  for  Ad5tg  and  Ad5∆∆,
averages ± SD, n=6, **p<0.0133
To determine if the pancreatic cancer cell lines MIA-PaCa-2 and AsPC-1 were
sensitive to the chemotherapeutic drugs gemcitabine and irinotecan, cell-
killing assays were performed with serial dilutions of chemodrugs.
MIA-PaCa-2 and AsPC-1 are sensitive to gemcitabine and irinotecan. A
dose-related cell death was observed 72 h after treatment with irinotecan in
both MIA-PaCa-2 and AsPC-1 (Fig. 12 A and B). Doses of 1mM irinotecan
resulted in 95-100% cell death in MIA-PaCa-2 and <80% cell death in AsPC-1.
Maximum dose of irinotecan, 34mM, did not result in an increase in cell death
in AsPC-1 (data not shown). The average EC50 for irinotecan (serial dilution
starting at 1mM) was 25µM (SD= 6, n= 6) in MIA-PaCa-2, and 38µM (SD=3.4,
n=4) in AsPC-1.
Treatment with gemcitabine caused <50% cell death in both cell lines. AsPC-1
showed more resistance to gemcitabine than MIA-PaCa-2. 100µM gemcitabine
resulted in <40% cell death in AsPC-1 whereas 1µM gemcitabine induced  30-
40% cell death in MIA-PaCa-2. Higher doses (40µM, 100µM, 1mM) did not
cause more than 50% cell death in MIA-PaCa-2. Since gemcitabine treatment
resulted in less than 50% cell death in both cell lines, no EC50-value could be
calculated. The average gemcitabine concentration causing 20% cell death was
39.5nM (SD= 2.7, n=6) in MIA-PaCa-2 and 200nM (SD= 64, n= 6) in AsPC-1
cells.34
MIA-PaCa-2
A
AsPC-1
B
Fig. 12 Dose-response curves to gemcitabine and irinotecan. A. Dose-response
curves in MIA-PaCa-2 cells. The graph is representative of 10 separate
experiments. B Dose-response curves in AsPC-1 cells. The graph is representative
of 6 separate experiments.35
To  determine  whether  the  adenoviral  mutants  Ad5tg  and  Ad5∆∆  could
enhance cell-killing in combination with suboptimal doses of gemcitabine and
irinotecan, cell-killing assays with combination treatments were performed in
both cell lines. The selected drug doses caused less than 20% cell death alone
and had been previously identified in dose-response curves to drug (Fig. 12 A
and B).
Cell-killing in MIA-PaCa-2 cells is enhanced by combining Ad5∆∆  with
gemcitabine or irinotecan. The Ad5∆∆ mutant in combination with either
gemcitabine or irinotecan resulted in increased cell death compared to Ad5∆∆
alone (Fig. 13 A and 14). The cell-killing was dose-dependent and significant
for Ad5∆∆ with gemcitabine (p<0.05) as for Ad5∆∆ with irinotecan (p<0.01).
The enhanced cell-killing in response to combination treatments with Ad5∆∆
was  observed  for  treatments  with:  constant  concentration  of
chemotherapeutic drug and serial dilution of virus (Fig. 14 A), and constant
concentration of virus and serial dilution of chemotherapeutic drug (Fig. 14
B).
Ad5tg in combination with suboptimal doses of irinotecan resulted in equal
or  increased  cell  death  compared  to  Ad5tg  alone.  However,  Ad5tg  in
combination with suboptimal doses of gemcitabine showed decreased cell-
killing compared to Ad5tg alone (Fig. 13B). Similar additive or antagonistic
effects has been previously observed in another cell line, PANC-1, in earlier
studies (Dr. Cherubini & Kallin, unpublished work).
Average  EC-50  values  calculated  on  dose-response  curves  to  virus  in
combination with different concentrations of drug relative to virus alone in
are shown in Fig. 15.36
A
Fig. 13 Dose-response curves to virus and chemodrug in MIA-PaCa-2. A. Ad5∆∆
in combination with gemcitabine and irinotecan. Selected graphs are
representative for experiments with same concentrations of virus and drug. EC50-
values from dose-response curves with same concentrations generated an
average EC50, which allowed comparison between virus alone and combination
treatments (Fig. 14). The values are corrected for cell death by drug alone.37
B
Fig. 13 Dose-response curves to virus and chemodrug in MIA-PaCa-2. B. Ad5tg
in combination with gemcitabine and irinotecan. Selected graphs are
representative for experiments with same concentrations of virus and drug. EC50-
values from dose-response curves with same concentrations generated an
average EC50, which allowed comparison between virus alone and combination
treatments (Fig. 14). The values are corrected for cell death by drug alone.38
A
B
Fig.  14 Enhanced dose-dependent cell-killing by Ad5∆∆+chemodrug. A. Dose-
response  curves  to  combination  treatments  with  constants  concentration  of
gemcitabine or irinotecan and serial dilutions of Ad5∆∆. The values are corrected
for cell death by drug alone. B. Dose-response curves to combination treatments
with  constant  concentrations  of  Ad5∆∆  and  serial  dilutions  of  gemcitabine  or
irinotecan. The values are corrected for cell death by virus alone.39
MIA-PaCa-2
Fig. 15 Combination treatments with constant concentrations of chemodrugs and
serial dilutions of viruses in MIA-PaCa-2 cells. Average ±SD calculated from EC50-
values  for  Ad5∆∆+gem,  Ad5∆∆+iri,  Ad5tg+gem  and  Ad5tg+iri  relative  to
averages of EC50-values for each virus alone. Ad5tg+gem 80nM gave too high
values to fit graph. *p<0.05 **<p0.01 x= no significance40
Cell-killing  in  ASPC-1  cells  is  enhanced  by  virus  in  combination  with
suboptimal doses of irinotecan. Combination treatment of both the Ad5tg and
Ad5∆∆ viruses with suboptimal doses of irinotecan (<20% cell death by drug
alone) resulted in enhanced cell-killing compared to virus alone. Combination
treatment  with  virus  and  suboptimal  doses  of  gemcitabine  showed  no
significant differences in cell-killing compared to virus alone. Average EC-50
values form dose-response curves (Fig. 15 A and B) allowed comparison
between different combination treatments and virus alone (Fig. 16).41
A
Fig. 15 Dose-response curves to virus and chemodrug in AsPC-1. A. Ad5∆∆ in
combination with gemcitabine and irinotecan. Selected graphs are representative
for experiments with same concentrations of virus and drug. EC50-values from
dose-response curves with same concentrations generated an average EC50,
which allowed comparison between virus alone and combination treatments (Fig.
16). The values are corrected for cell death by drug alone.42
B
Fig. 15 Dose-response curves to virus and chemodrug in AsPC-1. B. Ad5tg in
combination with gemcitabine and irinotecan. Selected graphs are representative
for experiments with same concentrations of virus and drug. EC50-values from
dose-response curves with same concentrations generated an average EC50,
which allowed comparison between virus alone and combination treatments (Fig.
16) The values are corrected for cell death by drug alone.43
ASPC-1
Fig. 16 Combination treatments with constant concentrations of chemodrugs and
serial dilutions of virus in AsPC-1 cells. Average ±SD calculated from EC50-values
for Ad5∆∆+gem, Ad5∆∆+iri, Ad5tg+gem and Ad5tg+iri relative to average on
EC50 for virus alone. *p<0.05 **<p0.01 x= no significance44
Adenoviral gene expression in the presence of chemotherapeutic drugs
To  determine  whether  the  chemotherapeutic  drugs  gemcitabine  and
irinotecan could affect the viral life cycle, cell lysates were analysed for
changes in viral gene expression focusing on E1A and adenoviral capsid
proteins.  E1A  is  expressed  early  in  infection  while  capsid  proteins  are
expressed in late stage of infection.
Adenoviral capsid proteins were expressed 48 hours after infection both for
virus alone and in combination with gemcitabine (Fig. 17 A). However, after
treatment with irinotecan, no expression could be detected after 48 hours (Fig.
17 B). Combination treatment with virus and irinotecan showed instead an
increase in expression of E1A. This suggests that the presence of irinotecan
caused an increase in early viral gene expression but a decrease, or delay, of
the formation of the viral capsid, which occurs in a late stage of the viral life
cycle.
Cells infected with Ad5∆∆, showed an increase in E1A expression compared
to cells infected with Ad5tg, the difference was obvious especially after 24 h
(Fig. 17 A and B).45
A
B
Fig. 17 Western blots of viral proteins in MIA-PaCa-2 cells treated with viruses in
combination with A. suboptimal dose (40nM) of gemcitabine and B. suboptimal
dose (15µM) of irinotecan.46
Cell cycle analysis
Parallel with the quantification of viral proteins, cell cycle analysis was
performed. The cell cycle was analysed to determine whether cell cycle
changes  could  be  involved  in  the  enhanced  cell  killing  in  response  to
combination treatments with Ad5∆∆.  MIA-PaCa-2 cells were analysed by
FACS at 24, 48 and 72 hours after treatment.
Increase in the polyploid cell population in cells infected with Ad5∆∆. As
described earlier, the viral mutant Ad5∆∆ caused enhanced cell-killing in
combination with gemcitabine, while Ad5tg combined with gemcitabine
caused a decrease in cell-killing. A difference in polyploid cells was observed
when  the  cell cycle  profile  for these  two  viruses  was compared.  Ad5∆∆
caused an increase in polyploidy over time (Fig. 22), which could not be
detected for cells treated with Ad5tg. This polyploidy, only observed in cells
treated with Ad5∆∆, was present also in combination with chemotherapeutic
drugs. Polyploidy might be one of the mechanisms behind the demonstrated
synergy of Ad5∆∆ in combination with gemcitabine. Ad5∆∆ in combination
with irinotecan also resulted in increased polyploidy compared to similar
combinations with Ad5tg. The presence of chemotherapeutic drugs did not
seem to affect the induction of polyploidy caused by Ad5∆∆.
Increase in the sub G1 fraction in cells infected with Ad5∆∆ in combination
with irinotecan. Irinotecan caused an increase in the G2/M-phase over time,
but in combination with Ad5∆∆ the increase in G2/M was absent and instead,
polyploidy was observed together with an increase in sub G1 (Fig. 21). In
combination with Ad5tg, the increase in G2/M still occurred, polyploidy did
not appreciably increase and sub G1 was similar to irinotecan alone.
The adenoviral mutant, Ad5∆∆, seemed to cause aberrations in the normal
cell cycle progression, which were not detectable in cells treated with Ad5tg.
Gemcitabine treatment resulted in an increased cell population in S-phase
after 48 hours (Fig. 18 and 19) while irinotecan treatment resulted in an
increased cell population in S-phase at 24 hours after treatment followed by
increased G2/M at 48 and 72 hours after treatment (Fig. 20 and 21).47
Fig. 18 Cell cycle profiles in cells treated with suboptimal doses of gemcitabine
(40nM) in combination with Ad5tg or Ad5∆∆ after 48 hours. M1= sub G1, M2= G1,
M3= S-phase, M4= G2/M and M5= polyploid cells. (Please note that M5 comes
after M1 in the graph legend.)48
Fig. 19 The percentage of cells in different phases of the cell cycle. Ad5tg and
Ad5∆∆ in combination with gemcitabine at 24, 48 and 72 hours. The graphs show
the percentage of cells in each stage of the cell cycle. (The sample for gem 72h
and  Ad5∆∆  72  hours  were  contaminated  and  cannot  be  shown.)49
Fig. 20 Cell cycle profiles in cells treated with suboptimal doses of irinotecan
(15µM) in combination with Ad5tg or Ad5∆∆ after 48 hours. M1= sub G1, M2= G1,
M3= S-phase, M4= G2/M and M5= polyploid cells. (Please note that M5 comes
after M1 in the graph legend.)50
Fig. 21 Percentage of cells in the different phases of cell cycle. Ad5tg and Ad5∆∆
in  combination  with  irinotecan  at  24, 48 and  72 hours.  The  graphs  show  the
percentage of cells in each stage of the cell cycle. (The sample for Ad5∆∆  72
hours was contaminated and cannot be shown.)51
Fig. 22 Increased polyploid cell population over time in cells treated with Ad5∆∆
and suboptimal doses (40nM) of gemcitabine compared to mock.52
Expression of proteins involved in mitosis in the presence of virus and
chemotherapeutic drugs
The changes in cell cycle progression that were demonstrated for treated cells
above, especially the polyploidy caused by Ad5∆∆, led to questions about
induction of mitosis. To determine whether virus and/or chemotherapeutic
drugs affected the expression of proteins essential for mitosis, cell lysates
were analysed for expression of the following proteins: Aurora A, Aurora B
and Mad 2.
Virus and chemotherapeutics increase the expression of mitotic proteins.
Aurora A-kinase expression was increased at both 24 and 48 hours in cells
treated with irinotecan (Fig. 23 B) and gemcitabine (Fig. 23 B) compared to
mock. The chemotherapeutic drugs in combination with viruses seemed to
further  increase  the  expression  of  Aurora  A-kinase.  A  minor  increase
compared to mock could be detected in cells treated with Ad5tg and Ad5∆∆
alone.
Aurora B was expressed to a greater extent in Ad5∆∆ alone than in Ad5tg
alone at both 24 and 48 hours. But the most visible increase was for both
chemotherapeutic drugs in combination with both viruses, especially after 48
hours. Since irinotecan induced expression on its own, it was hard to evaluate
if the combination with virus caused any further increase.
In untreated cells, the expression of Aurora B-kinase, and in some extent
MAD-2, declined after 48 hours. In contrast, the expression in virus infected
cells increased (Fig. 23 A and B).
Taken together, the expression of proteins involved in mitosis declined over
time for untreated cells in contrast to treated cells. Gemcitabine and irinotecan
induced expression of mitotic proteins, which would be compatible with the
results from previous cell cycle analysis. Both viruses showed a tendency to
induce expression as well.53
A
B
Fig. 23 Western blots of proteins involved in mitosis in MIA-PaCa-2 treated with
virus  in  combination  with  A.  suboptimal  dose  (40nM)  of  gemcitabine  and  B.
suboptimal dose (15µM) of irinotecan.54
Adenoviral replication in human umbilical-vein endothelial cells
To determine whether the viral mutant Ad5∆∆ replicates less than Ad5tg in
normal human umbilical-vein endothelial cells, quantitative polymerase chain
reaction and half maximum tissue culture infective dose were performed.
 Ad5∆∆ replicates in the same extent as Ad5tg in HUVEC . The results for
qPCR (Fig. 24 A) and TCID50 (Fig. 24 B) showed that Ad5∆∆ replicated in
HUVEC in the same extent as Ad5tg. Even though the 3 repeats of the qPCR
showed different CT-values (data not shown), the results showed the same
trend.  The  results  from  TCID50,  confirmed  the  result  qPCR  results.  The
replication was greatest for Ad5∆19K. The replication increased over time for
all viruses but the viral DNA declined at 72 hours after infection when cell
death increased. Previous work (unpublished work by Dr. Cherubini) has
shown  that  Ad5∆∆  replicated  less  than  Ad5tg  in  normal  human
bronchoepithelial cells (NHBE).
BrdU  incorporation  showed  that  HUVEC  was  not  growth  arrested
(performed by Dr. Cherubini). Taken this into account, these results showed
that  Ad5∆∆  replicated  in  proliferating  HUVEC.55
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Fig. 24 Adenoviral replication in human umbilical-vein endothelial cells A. Viral
DNA-quantification of Ad5∆19K,  Ad5∆∆ and Ad5tg in HUVEC at 24, 48 and 72
hours after infection. Expressed as fold change to Ad5tg at 24 hours. Viral uptake
control after 4 hours showed similar CT-value for all viruses. 1 out of 3 replicates
shown. B. Viral replication of Ad5∆19K, Ad5∆∆ and Ad5tg in HUVEC at 24, 48 and
72 hours after infection. Expressed as plaque forming units (PFU)/ml.56
DISCUSSION
The aims of this study were to investigate whether the E1ACR2- and E1B19K-
deleted virus, Ad5∆∆, in combination with chemotherapeutic drugs could
enhance  cell-killing  of  pancreatic  cancer  cells  and  if  so,  investigate
mechanisms  behind  the  enhancement.  In  this  report  I  demonstrate  that
Ad5∆∆  lyses  pancreatic  cancer  cells  in  vitro,  enhances  cell-killing  in
combination with chemotherapeutic drugs and induces polyploidy in infected
cells. In addition, I show that the presence of chemotherapeutic drugs has an
impact on viral gene expression and increases expression of proteins involved
in mitosis.
To achieve the replication-selectivity by deletions in E1A and E1B, some of
the  viral  cytotoxity  might  be  compromised.  The  cytotoxic  effect  was
significantly higher for wild type Ad5 (Ad5tg) than for the mutant Ad5∆∆ in
both MIA-PaCa-2 and AsPC-1 cells. The level of efficacy for Ad5∆∆ may not
be sufficient on its own. Previous studies have shown that Ad5∆19K (Leitner,
S. et al. 2009) and Ad5∆∆ (Oberg, D. et al. 2010) mutants can enhance cell-
killing in combination with the chemotherapeutic drug gemcitabine.   The
sensitization by Ad5∆19K has been demonstrated to be specific to cancer cells
(Leitner,  S. et al.  2009)  and  Ad5∆∆  was demonstrated to synergistically
increase docetaxel-induced cell-killing in prostate cancer cells (Oberg, D. et al.
2010).   Enhanced  cell-killing  was  also  demonstrated  for  Ad5∆∆  in
combination with the chemotherapeutic drug irinotecan (Dr. Cherubini &
Kallin, unpublished work).
I also found that, combining Ad5∆∆ with low doses of either gemcitabine or
irinotecan resulted in enhanced cell-killing in MIA-PaCa-2 cells. In AsPC-1
cells, cell-killing was enhanced with irinotecan but not with gemcitabine. The
different outcomes of combining Ad5∆∆ with gemcitabine in the two cell lines
could be due to differences in genetic aberrations in the two cell lines. In
contrast to MIA-PaCa-2, AsPC-1 cells are mutated in SMAD4. SMAD4 is57
involved in the tumour growth factor-beta (TGF-B) pathway and regulate cell
cycle progression from G1 to S-phase through suppressing Cyclin D. CDK2A,
mutated  in  both  cell  lines,  is  also  suppressing  Cyclin  D.  It  has  been
demonstrated that gemcitabine can prevent virus induction of S-phase cyclins
and cyclin D has been shown to decrease in the presence of gemcitabine
(Leitner, S. et al. 2009). This suggests that levels of cyclins might play a role in
the  cancer  cell’s  response  to  gemcitabine.  Previous  studies  have  shown
antagonistic effect of Ad5∆∆ combined with gemcitabine in PANC-1 cells (Dr.
Cherubini & Kallin, unpublished work), which are not mutated in SMAD4
(Sipos, B. et al. 2003), which suggest that the mechanisms of sensitivity and
resistance  are  more  complex  than  just  alteration  of  one  gene.  Chemo-
resistance to gemcitabine in pancreatic cancer has been demonstrated to
depend on for example the expression of Bcl2/adenovirus E1B19K interacting
protein (BNIP3). Drug-resistant cell lines expressed BNIP3 at lower levels
(Akada, M et al. 2005). According to this resistance-classification, both MIA-
PaCa-2 and AsPC-1 are intermediate sensitive to gemcitabine. Antagonistic
effects were demonstrated when Ad5tg was combined with gemcitabine, in
both cell lines. One theory, which might explain this, is that gemcitabine
inhibits viral replication (Leitner, S. et al. 2009). Relative to the combination
treatments,  Ad5tg  alone  showed  greater  efficacy.  This  suggests  that
gemcitabine might repress the replication of Ad5tg. However, no antagonistic
effect was observed when combining Ad5tg with irinotecan. In addition,
combination  treatments  with  irinotecan  caused  a  significantly  higher
enhanced cell-killing than gemcitabine for both viruses. Enhanced cell-killing
by virus in combination with irinotecan was also demonstrated in a previous
study  (Dr.  Cherubini  &  Kallin,  unpublished  work).  This  suggests  that
irinotecan could be a potential candidate for pancreatic cancer treatment in
combination with Ad5∆∆. This would be valuable in cancers that are resistant
to gemcitabine. For all cell viability assays in this project, virus and drug were
delivered to the cells at the same time point. Previous studies on MIA-PaCa-2
cells demonstrated synergistic effect when gemcitabine were delivered prior
to the virus, but antagonistic effects when the virus was delivered prior to
gemcitabine (Nelson, R. A. et al. 2009). This suggests that the order of delivery
could affect the efficacy and antagonism might be prevented.58
Gemcitabine is specifically targeting cells in S-phase causing premature chain
termination during DNA-synthesis. Irinotecan acts mainly during S-phase but
also in G2, by inhibiting Topoisomerase I, essential for religation of single
strand breaks during DNA-replication. E1A induces S-phase and is essential
for viral replication. The presence of either irinotecan or gemcitabine caused
increased E1A-expression for both Ad5tg and Ad5∆∆ at 24 and 48 hours.
These results indicate that both gemcitabine and irinotecan promote viral E1A
expression. One factor behind this could be increased viral uptake in response
to  the  drugs.  My  results  are  in  contrast  to  previous  studies,  which
demonstrated that gemcitabine decreased viral E1A expression at 48 hours for
Ad5tg and Ad5∆19K (Leitner, S. et al. 2009). Interestingly, the expression of
adenoviral capsid proteins, which reached detectable levels after 48 hours for
both  viruses,  was  inhibited  in  the  presence  of  irinotecan  but  not  with
gemcitabine. Taken together, irinotecan induced expression of early viral
genes  whilst  it  inhibited,  or  delayed,  the  expression  of  capsid  proteins,
essential for formation of the capsid. Gemcitabine had no detectable effect on
late viral proteins under these conditions.
In untreated cells there was a decline in S-phase over time, which suggest that
as cells get more confluent, cell proliferation decreases. This decline was
absent in cells treated with chemotherapeutic drugs. Gemcitabine caused
mainly an increase in S-phase over time, but also in G2/M compared to
untreated cells. Treatment with irinotecan caused increased cell population in
S-phase at 24 hours followed by increased G2/M-phase at 48 and 72 hours.
When combined with virus, both drugs showed a decrease in S-phase but
instead an increase in G2/M. Interestingly, cells infected with Ad5∆∆ caused
polyploidy, which increased over time. The presence of drugs did not seem to
affect the levels of polyploidy. In addition, Ad5∆∆  in combination with
irinotecan caused increased sub G1 fraction. These both phenomena could not
be observed for Ad5tg. Ad5tg combined with gemcitabine, which resulted in
an  antagonistic  effect  on  cell  death  showed  no  increase  in  polyploidy.
Polyploidy caused by Ad5∆∆ could be one factor enabling enhanced cell-
killing with drugs. Thus, Ad5∆∆ alone caused the same increase in polyploidy
after 48 hours, suggesting that polyploidy alone is not proportional to cell59
death.  However, sub G1 was increased in the presence of drug compared to
virus alone.
Since the population of cells in G2/M increased with all combinations, further
investigations of whether Ad5tg, Ad5∆∆, gemcitabine and irinotecan had an
impact on mitosis, expression of Aurora A-kinase, Aurora B-kinase and
MAD-2 were quantified. These proteins are essential for mitosis. In untreated
cells, the expression of Aurora B-kinase, and MAD-2, declined after 48 hours,
which supports previous results where S-phase and G2/M decreased over
time  in  untreated  cells.  In  contrast,  the  expression  of  all  three  proteins
increased over time in virus-infected cells. This suggests that viruses could
affect mitosis, which might contribute to the polyploidy. Both chemodrugs
increased the expression of Aurora A-kinase, which is involved in early
mitosis. Irinotecan greatly increased the expression of Aurora A-kinase and
Aurora B-kinase, further increases in combination with virus could not be
detected  under  these  conditions.  Gemcitabine,  especially  together  with
Ad5∆∆, seemed to increase the expression of Aurora A-kinase after 48 hours
and Aurora B-kinase at both 24 and 48 hours. Overall, these results suggest
that both irinotecan and gemcitabine induce mitosis and a tendency that both
viruses could stimulate mitotic protein expression to keep the cells cycling.
Ad5∆∆  was shown to lyse cancer cells and enhance cancer cell-killing in
combination  with  chemotherapeutic  drugs.  To  determine  whether
Ad5∆∆ replicates less than Ad5tg in normal HUVEC cells, viral replication
assays were performed. Surprisingly, Ad5∆∆ replicated to the same extent as
Ad5tg in the HUVEC cells. This suggested that the cells were not growth
arrested on the day of infection that was later verified by BrdU-uptake (Dr.
Cherubini). Proliferating cells provide similar intra-cellular environments as
cancer cells, therefore replication is less inhibited than in quiescent cells.
Previous studies using normal human bronchial endothelial cells (NHBE)
demonstrated that Ad5∆∆ replicated less than Ad5tg both in proliferating and
arrested  cells  (Dr.  Cherubini  &  Kallin,  unpublished  work).  It  would  be
valuable to study the replication of Ad5∆∆ in other normal cells, and also
repeat the replication assay in HUVEC using other methods to reach growth
arrest.60
Technical considerations
Many factors in an experiment affect the outcome of the results. The qPCR
results for viral DNA in the HUVEC cells were not entirely reproducible and
should be repeated to get more solid result. However, the trend was the same
in all experiments, and it answered the question whether Ad5∆∆ replicated in
HUVEC.  The  differences  between  experiments  were  possibly  due  to
unintentional loading of different amount of DNA. Even though the same
sample aliquots were used in the two first experiments, and the same volume
loaded, the CT-values were different. When pipetting very small volumes, a
small variation can cause big difference in the final concentration, such as an
undetected tiny air bubble in the tip for example. Inaccurate pipettes can also
be a problem, especially multichannel pipettes, where it is meant to be exactly
the same volume in each tip.
Inconsistent results of experiment-repeats occurred for some of the cell-killing
assays, even though the experiments were aimed to be exactly the same.
When the dilutions of chemodrugs and virus were prepared, here also, very
small volumes were used and small alterations in the actual concentration
might have occurred. Gemcitabine gave more inconsistent results in AsPC-1
than in MIA-PaCa-2. This could be due to the fact that AsPC-1 showed greater
resistance  than  MIA-PaCa-2,  but  it  is  plausible  that  alterations  in  cell-
metabolism  affect  the  results.  Cell  metabolism  differs  between  different
cancer cell lines, but also day to day due to the fact that they are living cells.
Passage  number  or  different  cell  concentration  could  influence  cell
metabolism. When the cells were plated for experiments, cell-counting was
performed manually under a light microscope. Even though the cells were
mixed prior to counting, the distribution could be uneven which could
generate a misleading number. Too many, or too few cells would then be
plated and the viral particles per cell you think you add, is actually not true.
Depending on the cell number, the distribution and uptake of drug and virus
might also alter. Over time I got to know my cells, suddenly odd cell-counts
were always re-counted to confirm the first number.61
Bacterial contamination was a problem in tissue culture for a while. The
samples for cell cycle analysis, Ad5∆∆ and gemcitabine at 72 hours were
contaminated and could therefore not be used. To have a complete cell cycle
analysis, the experiment for these conditions should be repeated. A low grade
contamination would have been worse, if the contamination is not noticed, it
will affect the results.
Future work
The viral replication of Ad5∆∆ should be analysed in MIA-PaCa-2 to complete
the  studies  of  the  virus  in  this  cell  line.  When  the  in  vitro  studies  are
completed, in vivo studies using MIA-PaCa-2 xenografts in immuno-deficient
mice should be performed: to investigate if the cell-death observed using
Ad5∆∆ combined with chemodrugs in vitro, will result in tumour regression
in  vivo.  Furthermore,  toxicology  studies  are  important  to  do  in  vivo, to
investigate if Ad5∆∆ is safe for normal cells, alone and in combination with
chemodrugs. It would be interesting to investigate the distribution of the
virus  in  the  tumour  and  surrounding  tissues  after  intratumoural  and
intravenous injections.
Conclusions
Chemotherapeutics show low efficacy in pancreatic cancer since the majority
of  cancers  are  resistant  to  drugs.  In  addition,  the  side  effects  of
chemotherapeutics are extensive.  The use of oncolytic replication-selective
adenoviruses in combination with low doses of chemotherapeutics is a novel
and promising approach to target pancreatic cancer.
This study suggests that the adenoviral mutant Ad5∆∆ in combination with
either gemcitabine or irinotecan is a potential treatment for pancreatic cancer.
Combination  treatments  with  irinotecan  could  be  an  alternative  to
gemcitabine in gemcitabine-resistant cancers.62
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 Appendix
1.  Western Blot Protocol (Dr. Gioia Cherubini)
WESTERN BLOT PROTOCOL
A. PREPARATION OF CELL LYSATES
•  Resuspend cell pellet in RIPA buffer
•  4º for at least 15-30’
•  Store at -20º or procede to complete lysates preparation
•  @ 10’ 13000rpm (or max speed) 4º
•  Bradford assay to quantify soluble proteins
•  Add Laemmli buffer 2X
•  Sonicate ~15’’ at max amplitude
•  @ 10’ 13000rpm (or max speed)
•  Store at -20º or proceed for western
B. PREPARATION OF GEL
•  Choose the % of gel that you want on the basis of the molecular weight of the
proteins you want to resolve (check on the outline, considering that you’ll do Trys-
Glycine gels)
•  Assemble the glass plates and spacers (1.5 mm thick)
•  Pour the running gel to about 0.1 cm below the wells of the comb (<10ml).
•  Seal with isopropanol.
•  When gel has set, pour off the isopropanol and absorb the leftover isopropanol with
3mm paper
•  Pour the stacking gel (~5 ml) and insert the comb immediately.
•  When the stacking gel has set, place in gel rig and immerse in buffer.
•  Prior to running the gel, flush the wells out thoroughly with running buffer.
C. PREPARE THE SAMPLES FOR THE RUN
•  Calculate the amount of sample you need to load ~30µg.
•  Boil for 5 min.
•  Cool at RT for 5 min.
•  Flash spin to bring down condensation prior to loading gel.
D. RUNNING THE GEL
•  After flash spinning the samples, load into the wells.
•  Be sure to use markers.
•  Run at 150 V.
•  Usual running time is about 1.5 hr.
E. MEMBRANE TRANSFER
•  Assemble "sandwich" for Bio-Rad's semi-dry Transblot.69
•  Prewet the extra-thick blotting paper, the membrane and the gel in 1x Transfer
buffer.
•  Transfer for 1 hr at 20V.
F. CHECKING THE EFFICIENCY OF TRANSFER
•  After transfer, wash the membrane with PBS to wash away the alcohol
•  Pour the Red Ponceau solution on the membrane and let it rock for a couple of min.
•  Recover the Ponceau solution.
•  Wash the membrane with a solution of TCA 0.5% for a couple of min.
•  Scan the membrane.
G. ANTIBODIES INCUBATION
•  Prepare the blocking buffer (PBS/0.1% TWEEN/5% MILK) and block for 1 hour RT
(room temperature).
•  Incubate with primary antibody diluted in Blocking buffer over night at 4º.
•  Wash 4 x 5 min with 0.1% Tween 20 in PBS.
•  Incubate with secondary antibody diluted in blocking buffer for 1hr at RT or 2 hr at
4º.
•  Wash 5-6 x 5 min with 0.1% Tween 20 in PBS.
H. DETECTION
•  Prepare a solution of the detection reagent with a mixture of 1:1 (consider ~2.5 ml per
membrane).
•  Pour the reagent drop to drop on the membrane to cover it completely and leave it
1min.
•  Put the membrane into a film cassette inside a plastic sheet, after removing the eccess
of reagent.
I. REVELATION
•  Put 2 films on top of each other and then on top of the membrane.
•  Close the cassette and wait 1 min (be careful to not move the films or you’ll get a
blurred image).
•  Put into the developer
2. Protocol for TCID50 (Heike Muller)
The TCID 50 procedure is part of the virus characterisation process; in particular it is used to
identify the infection rate of a virus. The cells used are always JH293 cells. The cells are first
seeded in a 96 well plate, left over night and then infected with the relevant virus in a dilution
series. Cells have to be counted before they are seeded, to ensure 10000 cells per well are
plated out. The cells previously grown in a T175 flask shout be 60-80% confluent and look
healthy (have a little haylo). Characterisation is always carried out in triplicates, at least two
viruses are used: a known control and the one to be characterised. Make fresh medium for
seeding!!!
Day 1
TCID50 is performed in triplicate for each virus i.e. 3 plates per virus. Usually TCID50 plates
are set up for two viruses at a time. Include an additional 3 plates for the control. As TCID50
can be read between 10 and 14 days if plates have been set up a couple of days beforehand
with a control included, an additional control does not have to be incorporated in the second
set-up.
Grow JH293 cells in T125 flasks in 10% FBS-E4 until 60-80% confluent. Use a cell passage
number between 5-25. Three T175 flasks will yield approximately 8.9xE7 cells. Grow more
cells than are required70
Disperse cells (per flask) by the addition of 5 ml trypsin/versene solution for 5 min at 37°C.
Once the cells are coming off the flak surface always add 5 ml (per flask) of E4+10% FCS to
stop the trypsin reaction. Disrupt cell layers into single cells by pipetting up and down
several times, transfer dispersed cells to 50 ml tissue culture tube and centrifuge at 1200-1500
rpm for 4 min in a table top swinging-bucket rotor. If more than one flask is used combine all
cell suspensions is one 50 ml tube.
Aspirate media and re-suspend cells in 10 ml 10% FBS-E4 (per flask). If only one flask is used,
suspend in 8ml only so to not over-dilute. Add 9ul of the cell suspension to a
haemocytometer. Count cells by haemocytometer and calculate cells/ml. Over-dilute the cells
with 10% FBS-E4 to aid counting. For 3 flasks – have a total cell stock volume of 50ml.
Calculate total number of cells in cell stock by multiplying by the volume.
Estimate total number of cells needed for assay e.g. one 96-well plate of 10000
cells/well/0.2ml = 960000 cells in 19.2 ml.  Make excess: 1xE6 cells in 20 ml per 96-well plate.
Dilute in culture media (10%FBS-E4). (10000 cells per well are required)
Total cells required = 1xE6 x no. of plates
Total volume of media = 20ml x no. of plates
Eg:  total number of plates required = 15, needed are 15x10
6 cells
Volume of media needed = 15x20 = 300 ml
Eg:  cells counted in 4x4 square (x2 average) = 266
Makes 266 x 10
4 cells per ml = 2.66x10
6 cells/ml
15x10
6 / 2.66x10
6 = 5.64 ml
Needed are 5.64 ml of cell suspension in 300 ml 10% E4
For each sample to be tested assay in triplicate 96-well plates and add another set of three
plates for the internal control = minimal assay is 6 plates for one sample.
Transfer diluted stock solution of cells (now at 50000cells/ml) into pipette trough. Use
multichannel (12 channels) pipettor to transfer 200µl of cell suspension to each well in the 96-
well plates.
Place cells in 37°C incubator (5% CO2) for 24 h.
Day 2
Just prior to sample additions (24h after plating cells) prepare the internal control dilutions.
The control is the Ad5 wild type CsCl-purified stock virus. This standard is in the range of
1xE11 –1xE12 pt/ml and is diluted serially in culture tubes as follows: 10µl in 10ml
(1/1000=10
-3), take 10µl of this dilution into 10ml (1/1000=10
-6), and finally take 500µl of this
dilution into 5ml (1/10=10
-7), all dilutions are in serum free E4 (E4 +0% FCS). The final
dilution factor of control virus is 1xE-7.
Transfer diluted control (10
-7) into pipetting trough. Is done in triplicates. Use multichannel
(12 channels) pipettor to transfer 20µl of diluted stock virus solution (diluted 1xE-7) to each
well in the first row of plate 1+2+3.  Pipette up and down 3 times and transfer 22µl to the
second row (row 2-7) in each of the plates. Repeat the serial 10-fold dilutions from row 1 to 7,
resulting in dilutions from 1xE-7 to 1xE-13. The last row on the plate is the negative control
with uninfected control cells without virus. (From one row to another each 1/10 dilution)71
(Repeat for plate 2 and 3 so that 3 plates with control virus are infected, do all at the same
time to save tips).
Dilute the viral sample to be tested. Start with a low dilution initially 1xE-2 dilution and
continue by infecting 3 plates as described previously by serial dilutions from 1xE-2 –1xE-8 in
the plate. For unknown samples (never tested before) another set of 3 plates are set up
starting at dilution 1xE-5 to 1xE-11 or if samples is very confluent and virus has been used
before dilutes to 10
-7, same as control)
Place the infected cells in 37°C CO2-incubator for 10-14 days, monitoring plates every second
day.
Score plates on day 10 under light microscope. Count wells displaying cytopathic effect (CPE)
in first row of plate, continue throughout the plate, until every well has been recorded
Enter number of infected wells for each dilution and each plate into Excel worksheet and
calculate TCID50 data after first verifying that the worksheet is correct and valid
ACCEPTANCE CRITERIA
If any sign of CPE is visible in a well it is counted as CPE. To score a well as not showing
 CPE there must no sign of CPE in any area of the well
If the variability of the internal control (standard Ad5 wild type) is within ± 1 log unit in
pfu/ml the assay is valid (compared to previous titration values).
If the variation of the internal control virus is greater than 1 log unit, or if the uninfected row
of cells demonstrates CPE the assay is not valid and must be repeated.
In each assay the number of replicates has to be 3 for each dilution and each sample and
include the standard virus and uninfected cells also in triplicates.